Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ALKS [NASD]
Alkermes plc
Index- P/E375.25 EPS (ttm)0.12 Insider Own0.70% Shs Outstand144.18M Perf Week-0.49%
Market Cap6.49B Forward P/E59.56 EPS next Y0.76 Insider Trans4.99% Shs Float143.13M Perf Month-3.58%
Income20.60M PEG18.58 EPS next Q0.10 Inst Own91.40% Short Float2.25% Perf Quarter-5.46%
Sales596.30M P/S10.89 EPS this Y118.20% Inst Trans0.03% Short Ratio2.38 Perf Half Y45.96%
Book/sh7.77 P/B5.80 EPS next Y50.00% ROA1.40% Target Price50.73 Perf Year51.51%
Cash/sh2.51 P/C17.92 EPS next 5Y20.20% ROE2.10% 52W Range24.42 - 54.25 Perf YTD10.75%
Dividend- P/FCF54.06 EPS past 5Y-35.60% ROI5.40% 52W High-17.00% Beta0.95
Dividend %- Quick Ratio5.20 Sales past 5Y19.00% Gross Margin69.40% 52W Low84.40% ATR2.40
Employees1250 Current Ratio5.70 Sales Q/Q13.70% Oper. Margin8.40% RSI (14)50.32 Volatility6.33% 5.68%
OptionableYes Debt/Eq0.34 EPS Q/Q-8.30% Profit Margin3.50% Rel Volume1.22 Prev Close42.83
ShortableYes LT Debt/Eq0.34 EarningsFeb 27 BMO Payout0.00% Avg Volume1.36M Price45.03
Recom2.50 SMA202.75% SMA50-4.50% SMA20015.10% Volume1,654,995 Change5.14%
10-Apr-14Upgrade Mizuho Neutral → Buy $55 → $61
09-Apr-14Reiterated MKM Partners Sell $32 → $35
28-Feb-14Reiterated UBS Neutral $42 → $53
28-Feb-14Reiterated MKM Partners Sell $26 → $32
28-Feb-14Reiterated Mizuho Neutral $33 → $56
05-Dec-13Downgrade UBS Buy → Neutral $37 → $42
01-Nov-13Reiterated Mizuho Neutral $30 → $33
30-Oct-13Initiated FBR Capital Mkt Perform $31
24-May-13Reiterated UBS Buy $32 → $37
24-May-13Downgrade MKM Partners Neutral → Sell
18-Apr-13Downgrade Mizuho Buy → Neutral $30 → $26
17-Apr-13Reiterated MKM Partners Neutral $23 → $25
23-Jan-13Downgrade MKM Partners Buy → Neutral
16-Nov-12Initiated Mizuho Buy $27
25-Jan-12Upgrade MKM Partners Neutral → Buy $19 → $20
23-Aug-11Upgrade UBS Neutral → Buy $20.50 → $21
08-Jul-11Reiterated UBS Neutral $19 → $20.50
07-Jun-11Reiterated UBS Neutral $16.50 → $19
10-May-11Reiterated UBS Neutral $14.50 → $16.50
20-Oct-10Downgrade Caris & Company Above Average → Average $16 → $10
16-Apr-14 09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks +5.14%
11-Apr-14 06:41AM  Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% Zacks
10-Apr-14 03:39PM  Gilead Announces Encouraging Sovaldi Data Zacks
08:21AM  [video] Alkermes is a true drug innovator: CEO at CNBC
05:57AM  Alkermes upgraded by Mizuho Briefing.com
09-Apr-14 06:45PM  Lightning Round: Citigroup, Disney & More at CNBC +7.53%
05:30PM  Oncolytics Reports Additional Data on Reolysin Zacks
11:48AM  Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns Zacks
10:50AM  Positive Trial Data Lifts Alkermes Zacks
08-Apr-14 03:33PM  Alkermes to seek schizophrenia drug approval after trial success Reuters
03:21PM  Alkermes to seek schizophrenia drug approval after trial success Reuters
01:06PM  Why Alkermes PLC Shares Temporarily Spiked Higher at Motley Fool
12:57PM  Alkermes Scores Phase 3 Win for Long-Lasting Schizophrenia Drug at Motley Fool
12:12PM  Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3 at Investor's Business Daily
11:57AM  Alkermes to seek schizophrenia drug approval after trial success Reuters
11:51AM  [$$] Alkermes Treatment for Schizophrenia Shows Positive Results at The Wall Street Journal
11:10AM  Halozyme Falls on Phase II Study Halt Zacks
10:53AM  UPDATE 1-Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
10:40AM  Bristol-Myers Seeks FDA Approval for HCV Candidates Zacks
09:26AM  RadNet Touches New 52-Week High Zacks
09:24AM  Ahead of the Bell: Alkermes shares jump AP
09:11AM  Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment at TheStreet
08:00AM  The Boston Beer Company Earnings Call scheduled for 8:00 am ET today CCBN
08:00AM  Novartis AG Earnings Call scheduled for 8:00 am ET today CCBN
08:00AM  Alkermes Conference Call to discuss Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil scheduled for 8:00 am ET today CCBN
07:10AM  Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
07:05AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:04AM  Alkermes announces phase 3 'positive' results from aripiprazole lauroxil study at theflyonthewall.com
07:00AM  Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
06:54AM  Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% Zacks
06:36AM  Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher Zacks
07-Apr-14 06:30PM  Balanced Risk-Reward for EMCOR Group Zacks
06:00PM  Halozyme Falls on Phase II Study Halt Zacks
05:25PM  Expense Woes Persist at ProAssurance Zacks
04-Apr-14 07:05AM  Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% Zacks -6.53%
03-Apr-14 05:20PM  Good News for Keryx Zacks -5.06%
05:15PM  Glaxo Stops MAGE-A3 Lung Cancer Study Zacks
03:55PM  Encouraging Results on Gilead's Sovaldi Zacks
07:21AM  What Falling Estimates & Price Mean for bluebird bio (BLUE) Zacks
06:45AM  Should You Get Rid of Synageva BioPharma (GEVA) Now? Zacks
02-Apr-14 08:02PM  Why Tesla Motors, Acceleron Pharma, and Ballard Power Systems Jumped Today at Motley Fool
04:55PM  Eli Lilly Signs Deal with Prasco Zacks
03:30PM  FDA Panel Positive on MannKind's Afrezza Zacks
02:06AM  TetraLogic Pharmaceuticals (TLOG) Soars: Stock Up 20.7% Zacks
02:01AM  Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% Zacks
01-Apr-14 03:45PM  Bayer's Adempas Cleared in the EU Zacks
02:15PM  Oxygen Biotherapeutics Up on FDA News Zacks
07:17AM  Alkermes recommended ahead of Phase 3 data at JPMorgan theflyonthewall.com
02:10AM  Celladon (CLDN) Jumps: Stock Up 5.9% Zacks
31-Mar-14 05:30PM  Glaxo Presents Darapladib Data Zacks +5.05%
04:08PM  Idera Soars on Phase II Drug Data Zacks
03:30PM  Endocyte Prices New Offering at $21 Per Share Zacks
28-Mar-14 02:38AM  Insmed Incorporated saw its shares rise more than 7% in the session. Zacks
27-Mar-14 06:43AM  China Cord Blood Corporation (CO) Soars: Stock Up 5.7% Zacks
25-Mar-14 03:30PM  Positive CHMP Opinion for Novo Nordisk's Drugs Zacks
02:32PM  Last Week's Biopharma R&D Winners at Motley Fool
24-Mar-14 05:30PM  Biogen's Alprolix Approved in Canada Zacks -5.53%
07:39AM  Gain Capital Holdings, Vail Resorts, Johnson & Johnson, Alkermes and Alexion Pharmaceuticals highlighted as Zacks Bull and Bear of the Day Zacks
02:12AM  AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 7.2% Zacks
21-Mar-14 11:54AM  Nasdaq Back Above Water; Green Plains Jumps at Investor's Business Daily
06:21AM  Oncolytics Biotech (ONCY) Jumps: Stock Rises 5% Zacks
05:46AM  Strength Seen in ZIOPHARM Oncology (ZIOP): Stock Up 11.8% Zacks
20-Mar-14 05:15PM  Genomic Health Unveils Oncotype DX Data Zacks
11:50AM  Positive Data on Novo Nordisk's N8-GP Zacks
01:58AM  Prothena (PRTA) Jumps: Stock Rises 27.5% Zacks
19-Mar-14 03:50PM  Novo Nordisk Extends Diabetes Operations Zacks
06:54AM  Acceleron Pharma (XLRN) Falls: Stock Drops 5.7% in Session Zacks
18-Mar-14 04:00PM  Pipeline Update from BioDelivery Sciences Zacks
03:45PM  Intercept Sees Weakness in Earnings Result Zacks
02:50PM  Amgen Scores Again with PCSK9 Inhibitor Zacks
08:20AM  Narrower-Than-Expected Loss at Relypsa Zacks
02:50AM  Horizon Pharma (HZNP) Jumps: Stock Rises 5.6% Zacks
17-Mar-14 07:25AM  Quarterly Changes to the NASDAQ Q-50 Index GlobeNewswire
14-Mar-14 05:00PM  First Laminoplasty Implant at Integra Zacks
12:45PM  Insider Trading Alert - KS, ALKS And LVS Traded By Insiders at TheStreet
12:45PM  Insider Trading Alert - KS, ALKS And LVS Traded By Insiders
10:40AM  Raptor Pharma Posts Wider-Than-Expected Q4 Loss Zacks
10:30AM  Ten Top Biotech Merger and Partnership Candidates
08:50AM  Narrower-than-Expected Q4 Loss at Repros Zacks
13-Mar-14 03:45PM  Bright Outlook at Bayer Zacks
03:45PM  Bright Outlook at Bayer
10:56AM  The Biotech Bubble: Is It or Isn't It? at Barrons.com
10:56AM  The Biotech Bubble: Is It or Isn't It?
10:30AM  AstraZeneca to Sell Cheshire Research Site Zacks
10:30AM  AstraZeneca to Sell Cheshire Research Site
08:30AM  Narrower Loss at Orexigen in Q4 Zacks
11-Mar-14 01:17PM  Regado Rises on REG1 Fast Track Designation Zacks
10-Mar-14 08:19AM  The Zacks Analyst Blog Highlights: RadioShack, Amazon.com, Best Buy, Conns and Alkermes Zacks
08:19AM  The Zacks Analyst Blog Highlights: RadioShack, Amazon.com, Best Buy, Conns and Alkermes
07-Mar-14 03:30PM  Pipeline Progress at Alkermes Zacks
03:30PM  Pipeline Progress at Alkermes
06:16AM  Why You Need to Pay Attention to Kamada (KMDA) Stock? Zacks
06:16AM  Why You Need to Pay Attention to Kamada (KMDA) Stock?
06-Mar-14 01:04PM  ALKERMES PLC. Financials EDGAR Online Financials
07:00AM  Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder Business Wire
07:00AM  Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder
06:46AM  Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% Zacks
06:46AM  Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5%
05-Mar-14 08:50AM  Narrower-than-Expected Q4 Loss at GTx Zacks
12:48AM  Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% Zacks
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.